Acute Graft-versus-host Disease
Conditions
Interventions
investigational material(s)
Generic name etc : INCB039110
INN of investigational material : Itacitinib
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigatio
Sponsors
Incyte Biosciences Japan G.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Japanese; subject was born in Japan and has not lived outside of Japan for a total of > 10 years, and subject can trace maternal and paternal Japanese ancestry. (2) Has undergone 1 allo-hematopoietic stem cell transplant (HSCT) from any donor and source (unrelated, sibling, haploidentical donors with any matching) using bone marrow, peripheral blood or cord blood for hematologic malignancies. Recipients of myeloablative and reduced-intensity conditioning regimens are eligible. (3) Clinically suspected Grades II to IV aGVHD as per Mount Sinai Acute GVHD International Consortium (MAGIC) criteria, occurring after allo-HSCT and any anti-GVHD prophylactic medication. (4) Evidence of myeloid engraftment. Use of growth factor supplementation is allowed. (5) Female subjects should agree to use medically acceptable contraceptive measures, should not be breastfeeding, and must have a negative pregnancy test before the start of study drug administration if of childbearing potential or must have evidence of non-childbearing potential by fulfilling protocol-defined criteria at screening.
Exclusion criteria
Exclusion criteria: (1) Has received more than 1 allo-HSCT. (2) Has received more than 2 days of systemic corticosteroids for aGVHD. (3) Presence of GVHD overlap syndrome. (4) Presence of an active uncontrolled infection (defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs, or radiographic findings attributable to infection; persisting fever without signs or symptoms will not be interpreted as an active uncontrolled infection). (5) Known human immunodeficiency virus infection. (6) Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires treatment or at risk for HBV reactivation. For subjects with negative HBsAg and positive total hepatitis B core antibody and for subjects who are positive for HCV antibody, HBV DNA and HCV RNA must be undetectable upon testing. (7) Evidence of relapsed primary disease or having been treated for relapse after the allo-HSCT was performed. (8) Any corticosteroid therapy (for indication other than GVHD) at doses > 1 mg/kg per day methylprednisolone or equivalent within 7 days of enrollment. (9) Severe organ dysfunction unrelated to underlying GVHD, including the following: -Cholestatic disorders or unresolved veno-occlusive disease of the liver. -Clinically significant or uncontrolled cardiac disease. -Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen. (10) Serum creatinine > 2.0 mg/dL or creatinine clearance < 40 mL/min measured or calculated by Cockroft-Gault equation (11) Received Janus kinase (JAK) inhibitor therapy after allo-HSCT for any indication. Treatment with a JAK inhibitor before allo-HSCT is permitted. (12) Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety Number of treatment-emergent adverse events Defined as any adverse event reported for the first time or worsening of a pre-existing event after first dose of study drug. | — |
Secondary
| Measure | Time frame |
|---|---|
| pharmacokinetics 1.Cmax of INCB039110.Maximum observed plasma concentration. 2.Cl/F of INCB039110.Apparent oral dose clearance. 3.Objective response rate. Defined as the proportion of participants demonstrating a complete response, very good partial response, or partial response. 4.Nonrelapse mortality. Defined as the proportion of participants who died due to causes other than malignancy. 5.Duration of response. Defined as the interval from first response until GVHD progression or death. 6.Time to response. Defined as the interval from treatment initiation to first response. 7.Malignancy relapse rate. Defined as the proportion of participants whose underlying malignancy relapses. 8.Failure-free survival. Defined as the proportion of participants who are still alive, have not relapsed, have not required additional therapy for aGVHD, and have not demonstrated signs or symptoms of chronic GVHD (cGVHD). 9.Overall survival. Defined as the interval from study enrollment to death due to any cause. | — |
Countries
Japan
Outcome results
None listed